title: High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro.
abstract: Nanocarriers have been explored to improve the delivery of tumor antigens to dendritic cells (DCs). Gold nanoparticles are attractive nanocarriers because they are inert, non-toxic, and can be readily endocytosed by DCs. Here, we designed novel gold-based nanovaccines (AuNVs) using a simple self-assembling bottom-up conjugation method to generate high-peptide density delivery and effective immune responses with limited toxicity. AuNVs were synthesized using a self-assembling conjugation method and optimized using DC-to-splenocyte interferon-γ enzyme-linked immunosorbent spot assays. The AuNV design has shown successful peptide conjugation with approximately 90% yield while remaining smaller than 80 nm in diameter. DCs uptake AuNVs with minimal toxicity and are able to process the vaccine peptides on the particles to stimulate cytotoxic T lymphocytes (CTLs). These high-peptide density AuNVs can stimulate CTLs better than free peptides and have great potential as carriers for various vaccine types.
authors: Department of Bioengineering, Rice University, 77005, Houston, TX USA. drezek@rice.edu.
authors: Adam Yuh
authors: AY
authors: Lin
authors: Jessica
authors: J
authors: Lunsford
authors: Adham Sean
authors: AS
authors: Bear
authors: Joseph Keith
authors: JK
authors: Young
authors: Phillip
authors: P
authors: Eckels
authors: Laureen
authors: L
authors: Luo
authors: Aaron Edward
authors: AE
authors: Foster
authors: Rebekah Anna
authors: RA
authors: Drezek
references: Crit Rev Oncol Hematol. 2008 Aug;67(2):93-102
references: 18400507
references: Clin Cancer Res. 2007 Jul 1;13(13):3776-82
references: 17606707
references: Macromol Biosci. 2006 Jul 14;6(7):506-16
references: 16921538
references: Nanoscale Res Lett. 2011 Apr 04;6(1):283
references: 21711861
references: Biochem Biophys Res Commun. 2005 Oct 14;336(1):84-92
references: 16126169
references: J Control Release. 2006 May 1;112(1):26-34
references: 16529839
references: Mol Immunol. 2009 Feb;46(4):743-8
references: 18996597
references: J Immunol Methods. 1997 Dec 29;210(2):167-74
references: 9520299
references: Biochemistry. 1966 Feb;5(2):467-77
references: 5942950
references: Biomaterials. 2009 Apr;30(10):1928-36
references: 19131103
references: J Control Release. 2005 Feb 16;102(3):551-61
references: 15681078
references: Nat Med. 2004 Sep;10(9):909-15
references: 15340416
references: J Transl Med. 2007 Apr 23;5:20
references: 17451606
references: J Nanopart Res. 2010 Jan;12(1):55-60
references: 21841911
references: Anal Biochem. 1990 Feb 15;185(1):131-5
references: 2344038
references: Nat Biotechnol. 2007 Oct;25(10):1159-64
references: 17873867
references: Clin Cancer Res. 2001 Oct;7(10):3012-24
references: 11595689
references: J Immunol. 2011 Feb 1;186(3):1325-31
references: 21248270
references: Biochem Biophys Res Commun. 2006 Jul 14;345(4):1365-71
references: 16725110
references: Nat Biotechnol. 2008 Jan;26(1):83-90
references: 18157119
references: Anal Chem. 2000 Nov 15;72(22):5535-41
references: 11101228
references: J Exp Med. 2003 Aug 18;198(4):569-80
references: 12925674
references: J Exp Med. 1998 Jul 20;188(2):277-86
references: 9670040
references: Bioconjug Chem. 2012 Apr 18;23(4):814-25
references: 22433013
references: Pharm Res. 2011 Feb;28(2):215-36
references: 20721603
references: J Immunol. 1995 Apr 15;154(8):3961-8
references: 7706734
references: Nat Mater. 2011 Mar;10(3):243-51
references: 21336265
references: Carbohydr Res. 2007 Feb 26;342(3-4):448-59
references: 17173881